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Pamidronate belongs to the class of nitrogen-containing bisphosphonates that are potent inhibitors of bone resorption
frequently used for the treatment of osteoporosis and cancer-induced osteolysis. The inhibition of osteoclasts’ growth has
been suggested as the main mechanism of the inhibitory effect of pamidronate on bone metastases. Recent ﬁndings indicated
that bisphosphonates also have a direct apoptotic effect on other types of tumour cells. Nitrogen-containing bisphosphonates
were shown to inhibit farnesyl diphosphate synthase, thus blocking the synthesis of higher isoprenoids. By this mechanism they
inactivate monomeric G-proteins of the Ras and Rho families for which prenylation is a functional requirement. On the
background of the known key role of G-proteins in tumorigenesis, we investigated a possible beneﬁcial use of pamidronate in
the treatment of malignant melanoma. Our results indicate that pamidronate inhibits the cell growth and induces apoptosis in
human melanoma cells in vitro. Susceptibility to pamidronate did not correlate to CD95 ligand sensitivity or p53 mutational
status. Furthermore it is interesting to note that overexpression of bcl-2 did not abolish pamidronate-induced apoptosis. These
data suggests that pamidronate has a direct anti-tumour effect on malignant melanoma cells, independently of the Bax/Bcl-2
level.
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At present, melanoma belongs to the most malignant tumours of
the skin and mucous membranes due to its aggressive biological
behaviour and tendency to generate early metastases. Malignant
melanoma is characterised by its relatively high therapeutical resis-
tance (Serrone and Hersey, 1999). Therefore, new therapeutical
strategies need to be established.
Monomeric G-proteins of the Ras and Rho families have been
shown to be involved in tumorigenesis and metastasis. Both Ras
and Rho GTPases are involved in key cellular processes, such as
reorganisation of the cytoskeleton, membrane trafﬁcking, lipid
metabolism, transcriptional regulation, cell growth, and apoptosis
(Aznar and Lacal, 2001). However, overexpression or constitutive
activation caused by mutations, rendering them insensitive to regu-
latory signals reveal the negative aspects of these multifunctional
proteins. The dysregulation of these GTPases triggers speciﬁc
signals that provoke uncontrolled cell growth, enhanced angiogen-
esis, inhibition of apoptosis, and genetic instability, all main aspects
of tumour development. Moreover, Rho family proteins are
engaged in regulation of the cytoskeleton and remodelling of
cytoarchitecture, which is a requirement of metastasis. Interest-
ingly, enhanced expression of several Rho family members was
observed in metastatic tumour cells (Suwa et al, 1998; Fritz et al,
1999; Clark et al, 2000). Recently, it was described that ectopic
overexpression of RhoC in A375 melanoma cell line was sufﬁcient
to create a highly metastatic phenotype (Clark et al, 2000).
For monomeric G-proteins of the Ras and the Rho families
prenylation is a functional requirement. The members of the Ras
superfamily are acylated and/or prenylated; the acyl/prenyl residues
function as membrane anchors when the G-proteins are released
from their complex with a guanine nucleotide dissociation inhibi-
tor. Recently, nitrogen-containing bisphosphonates were shown to
speciﬁcally inhibit farnesyl diphosphate synthase (van Beek et al,
1999; Bergstrom et al, 2000), the enzyme that executes the initial
condensation of isopentenyl diphosphate and dimethylallyl dipho-
sphate thereby inhibiting protein prenylation (Luckman et al,
1998). Thus, nitrogen-containing bisphosphonates interfere with
membrane localization of these proteins and may abolish signal-
mediation which can be of use in countering effects of their over-
expression or mutation.
Bisphosphonates are used for the treatment of bone metastases
and were initially thought to act via an inhibition of formation
of osteoclasts from immature precursor cells or direct inhibition
of resorption via induction of apoptosis in mature osteoclasts
(Hughes et al, 1995). Recently, evidence accumulated that bispho-
sphonates including pamidronate are potent inducers of apoptosis
in several cancer cell types such as myeloma (Shipman et al, 1997;
Aparicio et al, 1998), breast cancer (Senaratne et al, 2000) and
prostate cancer (Lee et al, 2001) but also in macrophage cell lines
(Rogers et al, 1996) and epithelial cell lines (Twiss et al, 1999).
These data indicate that the beneﬁcial effect of bisphosphonates
may result from a direct anti-tumour activity that may affect a
broad range of metastasing tumours.
In the present study, we demonstrate that micromolar concen-
trations of pamidronate inhibit cell proliferation and induce
apoptosis in different melanoma cell lines. The susceptibility to
CD95 ligand or the mutational status of p53 did not correlate with
the sensitivity to pamidronate. Moreover, overexpression of bcl-2
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Nevertheless, the apoptotic effect can be partially abolished by
coincubation with farnesol or geranylgeraniol conﬁrming the speci-
ﬁc effect of pamidronate on inhibition of prenylation.
MATERIALS AND METHODS
Materials
Pamidronate (3-amino-1-hydroxy-propylidene-1,1-bisphospho-
nate) was purchased from Novartis Pharmaceuticals Limited
(Basel, Switzerland). Anti-caspase-3 antibodies (rabbit) were
obtained from Pharmingen (Hamburg, Germany) and horseradish
peroxidase-conjugated secondary antibodies were purchased from
Dako (Hamburg, Germany). Farnesol and geranylgeraniol were
obtained from Sigma (Munich, Germany).
Cell culture
A375 cells (Giard et al, 1973) originate from primary tumour and
Mel2A (Bruggen et al, 1981), MeWo (Bean et al, 1975) and SkMel23
(Carey et al, 1976) originate from metastases. The two melanoma cell
populations M186 and M221 were obtained from patients with histo-
logically conﬁrmed metastatic melanoma by surgical intervention.
The generation and functionality of A375/pIRES and A375/mbcl-2
was described recently (Raisova et al, 2001). Melanoma cells were
grown in 90% Dulbecco’s Modiﬁed Eagle’s Medium (DMEM),
10% heat-inactivated foetal calf serum and supplemented with peni-
cillin (100 IU ml
71) and streptomycin (100 mgm l
71)i n7 5c m
2
tissue culture ﬂasks (Nunc, Wiesbaden, Germany). Prior to the
experiments, the cell lines were cultured for ﬁve passages under the
same seeding and growth conditions so as to achieve a comparable
growth behaviour. DMEM was purchased from Life Technologies
(Eggenstein, Germany); further cell culture reagents were obtained
from Seromed-Biochrom (Berlin, Germany).
Cytotoxicity assay
Cytotoxicity of pamidronate was determined by the release of
lactate dehydrogenase from the cytosol of damaged cells using an
LDH cytotoxicity detection kit (Roche Diagnostics, Mannheim,
Germany). Melanoma cells were seeded at a density of 40000 cells
per cm
2 and after 36 h treated with agents as indicated or corre-
sponding solvents as control. After incubation, the cell culture
supernatant was removed and clariﬁed by centrifugation at 400 g
for 5 min. Of the supernatants, 50 ml were transferred to microtiter
plates and diluted with 50 ml of PBS. After addition of 100 ml reac-
tion mixture containing 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-
phenyl tetrazolium chloride, diaphorase, NAD
+ and sodium lactate,
the samples were incubated for 30 min at room temperature,
protected from light. The extinction at 492 nm was measured using
an ELISA reader. The extinction values of control cells were set as
100% and the rate of lactate dehydrogenase release from treated
cells was calculated as per cent of control.
Cell proliferation assay
Melanoma cells were seeded at a density of 20000 cells per cm
2
and after 36 h treated with agents as indicated or corresponding
solvents as control. Cell proliferation was determined by staining
cells with crystal violet as described (Wieder et al, 1998). Brieﬂy,
non-adherent cells were washed off and the remaining cells were
ﬁxed with 0.1 M glutaraldehyde in PBS for 30 min. After washing,
the cells were incubated in 0.2 mM crystal violet in PBS for 30 min.
Unbound dye is washed off and 0.2% Triton X-100 is added to
release bound dye. The extinction of the supernatants at 570 nm
was measured using an ELISA reader. The extinction values of
vehicle-treated control cells were set as 100% and the rate of prolif-
eration of treated cells was calculated as per cent of control.
Cell death detection ELISA
Melanoma cells were seeded at a density of 40000 cells per cm
2 and
after 36 h treated with agents as indicated or corresponding solvents
as control. Apoptosis was determined quantitatively by using the
Cell Death Detection ELISA
Plus Assay (Roche Diagnostics,
Mannheim, Germany). Cells were centrifuged at 150 g for 5 min
and the supernatant was aspirated. Lysis buffer was added and the
cells incubated for 30 min. Then, a clear cytosolic supernatant was
prepared by centrifugation at 150 g for 10 min. Of the respective
supernatants, 20 ml were added to a streptavidin-coated microtiter
plate. After addition of 80 ml of a solution containing anti-histon-
biotin antibodies and anti-DNA-peroxidase antibodies in incubation
buffer, the samples were incubated under moderate shaking for 2 h.
Subsequently, the wells were washed three times with incubation
buffer, 100 ml of substrate solution were added and the plate was
incubated for up to 10 min at room temperature in the dark. The
absorption was measured at 405 nm using an ELISA reader. The
values of control cells were set as 100% and the apoptosis rates of
treated cells were calculated as per cent of control.
Immunoblotting
Cells were seeded at a density of 40000 cells per cm
2 in 25 cm
2
ﬂasks and after 36 h treated with agonist or corresponding solvents
for controls as stated. Subsequently, cells were scraped on ice in
150 mlo f5 0m M Tris×HCl, pH 7.2, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 3.5 mM SDS, 1 mM PMSF, 10 mM leupeptin
and 1 mM pepstatin. After homogenisation by sonication for 10 s,
samples were centrifuged for 10 min with 400 g at 48C. Aliquots
of the supernatant were mixed with SDS sample buffer (Laemmli,
1970) containing 0.1 M DTT instead of b-mercaptoethanol and
denatured for 5 min at 958C. After separation by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS–PAGE) and
transfer to nitrocellulose membrane the blot was incubated in
PBS containing 3% non-fat dried milk and 0.1% Tween 20 for
20 min to block nonspeciﬁc binding. The membrane was then
incubated with anti-caspase-3 antibodies 1:2000 in blocking buffer
for 2 h. Bound antibodies were detected after washing using
50 ng ml
71 horseradish peroxidase-conjugated secondary antibo-
dies in blocking buffer and the SuperSignal chemiluminescent
detection reagent (Pierce, Weiskirchen, Germany). Protein was
measured in samples diluted 1:5 in H2O using the BCA assay
(Pierce, Weiskirchen, Germany) with bovine serum albumin as
standard.
RESULTS
Inhibition of melanoma cell proliferation by pamidronate
To evaluate the effect of pamidronate on melanoma cells, four
different cell populations were chosen. A375 and M186 are
conﬁrmed to be sensitive to CD95 ligand as well as to ceramide
whereas Mel2A and M221 are resistant to these stimuli (Raisova
et al, 2000). Treatment with increasing concentrations of pamidro-
nate resulted in a concentration-dependent decrease in cell number
as assessed after 48 h (Figure 1). The greatest reduction in cell
numbers was observed at a concentration of 100 mM pamidronate
for A375, M186 and M221. Cell numbers were signiﬁcantly
reduced in the CD95 ligand-sensitive cell lines A375 with
83+4% of control and M186 with 89+4% of control as well as
in the CD95 ligand-resistant M221 with 76+4% of control. Cyto-
toxicity was excluded by measurement of LDH release into the cell
culture supernatant. Higher concentrations of 250 mM pamidronate
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of the CD95 ligand-resistant cell line Mel2A was not affected by
pamidronate at any of the used concentrations. These data suggest
that the observed effect on cell number is due to growth inhibition
and not primary cytotoxicity of pamidronate.
Apoptosis in melanoma cells after pamidronate treatment
One of the key features of apoptosis is the controlled degradation
of nuclear DNA, resulting in histone-bound DNA fragments
released into the cytoplasm of the cell. An ELISA assay was used
to measure these nucleosomes to achieve a quantiﬁcation of apop-
tosis. Treatment of melanoma cells with different concentrations of
pamidronate for 24 h led to a concentration-dependent increase of
DNA-fragmentation. As observed for inhibition of proliferation,
the effect was greatest with 100 mM pamidronate. The CD95
ligand-sensitive cell lines A375 and M186 showed an increase of
DNA-fragmentation after treatment with 100 mM pamidronate for
24 h to 330+20% of control and 154+5% of control, respectively
(Figure 2).
Induction of DNA-fragmentation was also shown in the CD95
ligand-resistant cell line M221 with 162+16% of control. However,
in agreement with the absence of an effect on cell number, the
CD95 ligand-resistant cell line Mel2A was also unaffected by pami-
dronate treatment in respect to DNA-fragmentation.
In contrast to pamidronate, clodronate, a non-amino bispho-
sphonate showed no effect on proliferation and apoptosis
induction in melanoma cell lines at the same concentration range
(data not shown). It is interesting to note that incubation of mela-
noma cells with 100 mM pamidronate for only 6 h, followed by an
18 h medium chase, resulted in nearly the same apoptotic effect as
the 24 h incubation with the drug (Figure 3). This short time effect
would correspond to the peak levels of circulating bisphosphonate
observed in clinical practice.
In order to investigate a possible synergistic effect of pamidro-
nate and DTIC, a standard chemotherapeutical agent used in
melanoma, A375 and M186 melanoma cell lines were incubated
for 24 h with 100 mM pamidronate, with 5 mgm l
71 DTIC and
with pamidronate plus DTIC, respectively. These experiments indi-
cate that 100 mM pamidronate has a greater proapoptotic effect
than 5 mgm l
71 DTIC. However, the combination of both
compounds failed to show any synergistic or additive effect in
apoptosis induction. The results were similar in the two cell lines
studied; the results in A375 are shown in Figure 4.
Caspase-3 is activated in pamidronate-induced apoptosis
Activation of the executor-caspases -3, -6 or -7 is a further key-step
in apoptosis. Their activation by proteolytic processing is the
point-of-no-return in the commitment to apoptosis. Western blot
was performed using anti caspase-3 antibodies that detect the
proenzyme and cleaved enzyme forms. Cells were treated with
100 mM pamidronate or vehicle for 24 h and in case of A375 with
the CD95-agonistic monoclonal antibody CH-11 as a positive
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Figure 1 Effect of pamidronate on melanoma cell proliferation. A375,
M186, Mel2A and M221 melanoma cells were seeded at a density of
20000 cells per cm
2 and after 36 h treated with indicated concentrations
of pamidronate or vehicle control for 48 h. Proliferation was measured
using crystal violet staining of adherent cells. Cell growth of control cells
was set as 100% and proliferation of treated cells was calculated as a per-
centage of control. Values represent the mean of four experiments+s.d.
350
300
250
200
150
100
50
0
D
N
A
-
f
r
a
g
m
e
n
t
a
t
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
A375 M186 Mel2A M221
Vehicle control
100 µM Pamidronate
Figure 2 Apoptosis of melanoma cells after pamidronate treatment.
A375, M186, Mel2A and M221 melanoma cells were seeded at a density
of 40000 cells per cm
2 and after 36 h treated with vehicle control or
100 mM pamidronate for 24 h. DNA-fragmentation was quantiﬁed using
an enzyme-linked immunoassay detecting cytoplasmic nucleosomes.
DNA-fragmentation of control cells was set as 100% and DNA-fragmenta-
tion of treated cells was calculated as a percentage of control. Values repre-
sent the mean of four experiments+s.d.
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Figure 3 Apoptosis after short term exposure of A375 cells to pamidro-
nate. A375 melanoma cells were seeded at a density of 40000 cells per
cm
2 and the next day treated with vehicle or 100 mM pamidronate. Cells
were either treated for 6 h with pamidronate, after which drug-containing
medium was replaced with fresh culture medium, and the cells were further
incubated for another 18 h or incubated with the drug containing medium
for 24 h. Apoptosis was then measured as DNA-fragmentation using an
enzyme-linked immunoassay detecting cytoplasmic nucleosomes. DNA-
fragmentation of control cells was set as 100% and DNA-fragmentation
of treated cells was calculated as a percentage of control. Values represent
the mean of four experiments+s.d.
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cleaved forms of 20 and 17 kDa. The CD95 ligand-sensitive cell
lines A375 and M186 show cleaved forms after pamidronate-treat-
ment but not in vehicle controls. This is conﬁrmed by cleavage of
procaspase-3 after treatment of A375 with CH-11. M221, a CD95
ligand-resistant cell line exhibits cleaved forms of caspase-3 after
pamidronate-treatment. Furthermore, in correlation to the results
for cell proliferation and DNA-fragmentation, the CD95 ligand-
resistant cell line Mel2A shows no activation of caspase-3 (Figure
5).
p53 mutation or bcl-2 overexpression do not abolish
pamidronate-induced apoptosis
Two frequent mechanisms by which tumour cells achieve chemore-
sistance were tested for their effect on pamidronate-induced
apoptosis. The two melanoma cell lines MeWo and SkMel23
harbour a mutated p53 gene (Raisova et al, 2001). Mutations in
this gene can render tumour cells insensitive to radiotherapy and
chemotherapy. In agreement, these cell lines were shown to be
resistant to CD95- and ceramide-induced apoptosis (Raisova et
al, 2001). The cells were treated for 24 h with 100 mM pamidronate
and apoptosis was quantiﬁed in terms of DNA-fragmentation. Both
cell lines were sensitive to pamidronate treatment with DNA-frag-
mentation of 320+20% of control and 450+50% of control for
MeWo and SkMel23, respectively (Figure 6A).
Shifting the ratio of the proapoptotic protein bax to the antia-
poptotic protein bcl-2 is another mechanism by which tumour
cells escape the immune system and achieve resistance against
drugs entering the mitochondrial apoptotic pathway. This resis-
tance can be mimicked in cell culture by ectopic overexpression
of bcl-2. A375 cells stably overexpressing murine bcl-2a (A375/
mbcl-2) and A375 transfected with vector only (A375/pIRES) as
control were treated for 24 h with 100 mM pamidronate. A375/
mbcl-2 in contrast to A375/pIRES were shown to be resistant to
CD95- as well as ceramide-induced apoptosis (Raisova et al,
2001). However, 100 mM pamidronate induced DNA-fragmentation
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Figure 4 Effect of combination of pamidronate with DTIC. A375 mela-
noma cells were seeded at a density of 40000 cells per cm
2 and the next
day treated with 100 mM Pamidronate, 5 mgm l
71 DTIC or both. After
24 h of incubation apoptosis was measured. DNA-fragmentation of control
cells was set as 100% and DNA-fragmentation of treated cells was calcu-
lated as a percentage of control. Values represent the mean of four experi-
ments+s.d.
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Procaspase-3
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Figure 5 Procaspase-3 cleavage upon pamidronate treatment in mela-
noma cells. A375, M186, Mel2A and M221 melanoma cells were seeded
at a density of 40000 cells per cm
2 and after 36 h treated with 100 mM
pamidronate (+), vehicle control (7)o r1mgm l
71 of the CD95-agonistic
monoclonal antibody CH-11 (C) as a positive control for 24 h. Whole cell
lysates were prepared and 50 mg of each were separated on a 15% SDS–
PAGE. After transfer to nitrocellulose the membrane was probed with anti
caspase-3 antibodies recognising procaspase-3 and cleavage products form-
ing active caspase-3 respectively. Immunocomplexes were detected using
Super Signal chemiluminescence reagent.
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Figure 6 Induction of apoptosis in p53-mutated and bcl-2 overexpres-
sing melanoma cells by pamidronate. (A) The p53-mutated cell lines
MeWo and SkMel23 and (B) the mock-transfected A375/pIRES and the
bcl-2 overexpressing A375/mbcl-2 were seeded at a density of 40000 cells
per cm
2 and after 36 h treated with vehicle control or 100 mM pamidro-
nate for 24 h. DNA-fragmentation was quantiﬁed using an enzyme-linked
immunoassay detecting cytoplasmic nucleosomes. DNA-fragmentation of
control cells was set as 100% and DNA-fragmentation of treated cells
was calculated as a percentage of control. Values represent the mean of
four experiments+s.d.
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with 509+53% of control (Figure 6B).
Geranylgeraniol abolishes pamidronate-induced apoptosis
The most prominent effect of pamidronate is the inhibition of
farnesyl diphosphate synthase, abolishing all isoprenoid biosynth-
esis (van Beek et al, 1999). To speciﬁcally circumvent the effect
of pamidronate on isoprenoid biosynthesis, cells were supplemen-
ted with farnesol or geranylgeraniol. Farnesol can be used as a
precursor for synthesis of all higher isoprenoids and protein-farne-
sylation whereas geranylgeraniol only supplies ubiquinone
biosynthesis and protein-geranylgeranylation. The addition of
increasing concentrations of either farnesol or geranylgeraniol in
the presence of pamidronate reduced pamidronate-induced DNA-
fragmentation in A375 cells in a concentration-dependent manner
(Figure 7). Farnesol or geranylgeraniol at a concentration of 10 mM
had no impact on pamidronate-induced apoptosis. At a concentra-
tion of 50 mM, farnesol reduced the apoptotic effect of pamidronate
by about 50% and 50 mM geranylgeraniol reduced DNA-fragmenta-
tion induced by pamidronate by 75%. However, higher
concentrations of 100 mM only slightly further decreased pamidro-
nate-induced apoptosis.
DISCUSSION
In this study, we demonstrate that treatment of melanoma cell lines
with the nitrogen-containing bisphosphonate pamidronate in vitro
induces apoptosis and inhibits proliferation of human melanoma
cells in a concentration-dependent manner. In contrast, clodronate,
a non-amino bisphosphonate, had no effect in melanoma cell lines
at the same concentration range. Furthermore, induction of apop-
totic DNA-fragmentation was paralleled by caspase-3 cleavage in
these cell lines. The CD95 ligand-sensitive cell lines A375 and
M186 as well as the CD95 ligand-resistant cell lines M221, MeWo
and SkMel23 showed DNA-fragmentation upon treatment with
100 mM pamidronate. This concentration of pamidronate has also
been shown to induce apoptosis in other cell lines, e.g. myeloma
(Shipman et al, 1997), breast cancer (Senaratne et al, 2000), and
prostate cancer (Lee et al, 2001). However, the CD95 ligand-resis-
tant cell line Mel2A was not affected by this bisphosphonate. A
speciﬁc apoptotic effect of pamidronate was further conﬁrmed by
the observation that caspase-3 is cleaved and therefore activated
in pamidronate-treated cells. Again, Mel2A showed no caspase-3
processing upon treatment with pamidronate. MeWo and SkMel23
harbour a mutated p53 gene that is a rather rare event in melano-
ma. Other tumours show frequent mutation in this gene, which
often leads to resistance against chemotherapy. The susceptibility
of these cell lines to pamidronate suggests a p53-independent path-
way of apoptosis-induction for this drug. Experimental settings
using bcl-2 antisense oligonucleotide therapy revealed an inverse
correlation between chemosensitivity of melanoma cells and bcl-2
levels (Jansen et al, 1998). These ﬁndings indicate that the bcl-2
protein levels contribute to drug resistance. Our investigations of
a bcl-2 overexpressing A375 cell line revealed that bcl-2 overexpres-
sion could not abolish the apoptosis triggered by pamidronate.
This proposes that pamidronate-induced apoptosis is a process
independent of mitochondrial activation.
Nitrogen containing bisphosphonates were shown to inhibit the
farnesyl diphosphate synthase probably by mimicking the dipho-
sphate moiety (van Beek et al, 1999). They are therefore
inhibitors of the synthesis of higher isoprenoids like geranylgeranyl
diphosphate. The prenylation of monomeric G-proteins such as
members of the Ras superfamily like Rho proteins was shown to
be reduced by bisphosphonate treatment. Geranylgeranylation of
these proteins is required for their proper membrane association
and hence activity. Rho family proteins are engaged in cytoskeletal
reorganisation and enhanced expression of several isoforms was
observed in metastatic tumour cells (Fritz et al, 1999). Moreover,
ectopic overexpression of the Rho protein RhoC in A375 melano-
ma cells was sufﬁcient to create a highly metastatic phenotype
(Clark et al, 2000). Therefore, the inhibition of Rho proteins might
provide a possibility to reduce metastasis through interference with
this pathway. The involvement of the inhibitory effect of pamidro-
nate on isoprenoid biosynthesis in induction of apoptosis was
tested using farnesol and geranylgeraniol to circumvent the block-
ade of geraniol synthesis. Geranylgeraniol was more potent in
abolishing pamidronate induced-apoptosis than farnesol. Supplying
geranylgeraniol reduced apoptosis by about 75%, suggesting gera-
nylgeranylated proteins such as Rho proteins to be the main
target of the pamidronate-effect. The participation of the mevalo-
nate pathway in bisphosphonate-induced apoptosis was also
demonstrated in mouse macrophages (Luckman et al, 1998) and
human myeloma cells (Shipman et al, 1998). An alternative
mechanism of action has been described for the non-amino
bisphosphonate clodronate (Frith et al, 1997). The incorporation
of bisphosphonates into ATP generates non-hydrolyzable toxic
analogues. This pathway may also in part account for the action
of nitrogen-containing bisphosphonates. However, in our experi-
ments, clodronate in the same concentration range as pami-
dronate failed to induce apoptosis in melanoma cell lines
Nitrogen-containing bisphosphonates with a similar bone
protective potency to pamidronate at concentrations of several
magnitudes less than required for pamidronate treatment have
been described (Rogers et al, 2000). Different bisphosphonates
are now introduced in clinical practice. For the use as chemother-
apy, a major drawback of bisphosphonates is their high afﬁnity to
hydroxyapatite on the bone surface, which makes them preferen-
tially delivered to sites of increased bone formation or
resorption. Animal studies revealed that the skeletal uptake of alen-
dronate reaches 90% of peak values within 1 h of intravenous or
oral administration (Lin et al, 1991). This could limit their thera-
peutic applicability to the treatment of bone metastasis.
Nevertheless, the issue of a survival beneﬁt is still controversial
(Wingen et al, 1986; Hall and Stoica, 1994; Diel et al, 1998). There-
fore, new derivates with an increased bioavailability are required to
extend the therapeutic spectrum of bisphosphonates.
Our ﬁndings show for the ﬁrst time that pamidronate has a
direct effect on melanoma cells, which is not blocked by overex-
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
500
400
300
200
100
0
D
N
A
 
f
r
a
g
m
e
n
t
a
t
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
) Farnesol
Geranylgeraniol
100 µM Pamidronate     –               +                +               +                +
Isoprenoid (µM)             0               0               10              50             100
Figure 7 Effect of isoprenoids on pamidronate-induced apoptosis in
melanoma cells. A375 melanoma cells were seeded at a density of
40000 cells per cm
2 and after 36 h treated with 100 mM pamidronate in
the presence of indicated concentrations of farnesol, geranylgeraniol or ve-
hicle control for 24 h. DNA-fragmentation was quantiﬁed as cytoplasmic
nucleosomes using an enzyme-linked immunoassay. DNA-fragmentation
of control cells was set as 100% and DNA-fragmentation of treated cells
was calculated as a percentage of control. Values represent the mean of
four experiments+s.d.
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bisphosphonates could be a promising novel therapeutic class for
the treatment and/or prevention of melanoma metastases.
Although our results suggest that pamidronate has no synergistic
effect with the classical chemotherapeutical agents such as DTIC,
possible alternative combinations of chemotherapy and bispho-
sphonates should be further investigated. Further studies are also
necessary to elucidate the underlying mechanism of their proapop-
totic effect in more detail and to establish the potential
antitumoural role of different bisphosphonate derivatives in human
melanoma.
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